Evidence use for product withdrawal is leaning toward observational research
With vaccination calls and medicine restrictions never far away from headlines, the spotlight is firmly on pharmacovigilance practices and decisions.
Before they get to market, drugs and medicines are subject to rigorous evaluation for their quality, safety and efficacy.
Years of work goes into ensuring the safety of each dose. Decisions to withdraw pharmaceuticals from the market are just as weighty and hinge on a thorough examination of all available evidence to strike a balance between benefits and risks.
Check out the rest of this feature here
Source link
#eliminator #PharmaTimes
